Abivax (ABVX) Retained Earnings (2021 - 2026)

Abivax's Retained Earnings history runs 6 years deep, the most recent figure standing at -$838.1 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 83.52% year-over-year to -$838.1 million in Q1 2026; TTM through Mar 2026 was -$838.1 million, a 83.52% decrease from a year earlier, with the FY2025 full-year figure at -$468.4 million, down 64.77% from the prior year.
• Retained Earnings declined to -$838.1 million in Q1 2026 per ABVX's latest filing, from -$468.4 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$84.4 million in Q4 2022 and bottomed at -$838.1 million in Q1 2026.
• The 5-year median for Retained Earnings is -$456.7 million (2025), against an average of -$392.9 million.
• Across the five-year window, Retained Earnings slumped 92.92% in 2024 and plunged 65.66% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$84.4 million in 2022, then plunged by 72.27% to -$145.5 million in 2023, then slumped by 92.92% to -$280.7 million in 2024, then plunged by 66.89% to -$468.4 million in 2025, then plunged by 78.93% to -$838.1 million in 2026.
• Per Business Quant, the three latest ABVX Retained Earnings figures stand at -$838.1 million (Q1 2026), -$468.4 million (Q4 2025), and -$485.9 million (Q3 2025).